Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomized phase II trial with infliximab (Remicade) in low-risk myelodysplastic syndrome
2005-000679-16Phase 2Completed
- Sponsor
- European Organisation for Research and Treatment of Cancer
- Start
- Mar 2005
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised trial of infliximab in myelodysplastic syndrome (MDS) (2 arms), sponsored by European Organisation for Research and Treatment of Cancer. Primary endpoint: Response rate. Started Mar 2005; status: completed.
02
Drugs
infliximab
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on 2005-000679-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-000679-16.